Bali Muralidhar is Director at Reneo Pharmaceuticals, Inc. (RPHM). They have made 11 open-market trades across 3 companies since 2019, most recently 2022-05-19.
CIK 0001784138
11 open-market purchases totalling $11.3M since 2019, never a sale. Across 11 scored buys the stock is down 19.0% at ninety days, and 21.1 points behind the S&P over the same stretch.
11 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 55% | 9% | 18% |
| Avg Move | +1.1% | -6.7% | -19.0% |
| Alpha | +0.8% | -8.7% | -21.1% |
| Scored | 11 | 11 | 11 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XCUR | BUY | 2022-05-19 | 2022-05-19 | $0.19 | $559K | -15.3% | -16.8% | -49.9% |
| RPHM | BUY | 2021-07-14 | 2021-07-15 | $8.50 | $950K | +1.5% | -5.4% | -23.9% |
| RPHM | BUY | 2021-06-23 | 2021-06-25 | $9.28 | $384K | -8.4% | -6.9% | -14.9% |
| RPHM | BUY | 2021-06-21 | 2021-06-23 | $8.93 | $845K | -4.7% | -6.7% | -20.2% |
| RPHM | BUY | 2021-06-08 | 2021-06-10 | $9.50 | $315K | -14.0% | -15.7% | -4.1% |
| RPHM | BUY | 2021-06-03 | 2021-06-07 | $9.25 | $114K | +4.9% | -8.0% | -10.8% |
| RPHM | BUY | 2021-05-28 | 2021-06-02 | $9.50 | $133 | +10.4% | -12.4% | +4.3% |
| RPHM | BUY | 2021-05-26 | 2021-05-28 | $9.37 | $121K | +2.6% | -8.0% | -39.8% |
| RPHM | BUY | 2021-04-13 | 2021-04-15 | $15.00 | $3.0M | +3.2% | -39.4% | -33.7% |
| SPRB | BUY | 2020-10-14 | 2020-10-16 | $15.00 | $3.0M | +34.0% | +54.9% | +46.9% |
| XCUR | BUY | 2019-12-19 | 2019-12-23 | $2.75 | $2.0M | -1.7% | -8.6% | -62.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.